PortalPublikationenLigand-Receptor Interactions of Galectin-9 and VISTA Suppres...

Ligand-Receptor Interactions of Galectin-9 and VISTA Suppress Human T Lymphocyte Cytotoxic Activity

Standard

Ligand-Receptor Interactions of Galectin-9 and VISTA Suppress Human T Lymphocyte Cytotoxic Activity. / Yasinska, Inna M; Meyer, N Helge; Schlichtner, Stephanie; Hussain, Rohanah; Siligardi, Giuliano; Casely-Hayford, Maxwell; Fiedler, Walter; Wellbrock, Jasmin; Desmet, Cloe; Calzolai, Luigi; Varani, Luca; Berger, Steffen M; Raap, Ulrike; Gibbs, Bernhard F; Fasler-Kan, Elizaveta; Sumbayev, Vadim V.

in: FRONT IMMUNOL, Jahrgang 11, 20.11.2020, S. 580557.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Yasinska, IM, Meyer, NH, Schlichtner, S, Hussain, R, Siligardi, G, Casely-Hayford, M, Fiedler, W, Wellbrock, J, Desmet, C, Calzolai, L, Varani, L, Berger, SM, Raap, U, Gibbs, BF, Fasler-Kan, E & Sumbayev, VV 2020, 'Ligand-Receptor Interactions of Galectin-9 and VISTA Suppress Human T Lymphocyte Cytotoxic Activity', FRONT IMMUNOL, Jg. 11, S. 580557. https://doi.org/10.3389/fimmu.2020.580557

APA

Yasinska, I. M., Meyer, N. H., Schlichtner, S., Hussain, R., Siligardi, G., Casely-Hayford, M., Fiedler, W., Wellbrock, J., Desmet, C., Calzolai, L., Varani, L., Berger, S. M., Raap, U., Gibbs, B. F., Fasler-Kan, E., & Sumbayev, V. V. (2020). Ligand-Receptor Interactions of Galectin-9 and VISTA Suppress Human T Lymphocyte Cytotoxic Activity. FRONT IMMUNOL, 11, 580557. https://doi.org/10.3389/fimmu.2020.580557

Vancouver

Yasinska IM, Meyer NH, Schlichtner S, Hussain R, Siligardi G, Casely-Hayford M et al. Ligand-Receptor Interactions of Galectin-9 and VISTA Suppress Human T Lymphocyte Cytotoxic Activity. FRONT IMMUNOL. 2020 Nov 20;11:580557. https://doi.org/10.3389/fimmu.2020.580557

Bibtex

@article{2f1cbf8446364d0195cdb5cba6edea42,
title = "Ligand-Receptor Interactions of Galectin-9 and VISTA Suppress Human T Lymphocyte Cytotoxic Activity",
abstract = "Acute myeloid leukemia (AML), a blood/bone marrow cancer, is a severe and often fatal malignancy. AML cells are capable of impairing the anti-cancer activities of cytotoxic lymphoid cells. This includes the inactivation of natural killer (NK) cells and killing of T lymphocytes. Here we report for the first time that V-domain Ig-containing suppressor of T cell activation (VISTA), a protein expressed by T cells, recognizes galectin-9 secreted by AML cells as a ligand. Importantly, we found that soluble VISTA released by AML cells enhances the effect of galectin-9, most likely by forming multiprotein complexes on the surface of T cells and possibly creating a molecular barrier. These events cause changes in the plasma membrane potential of T cells leading to activation of granzyme B inside cytotoxic T cells, resulting in apoptosis.",
author = "Yasinska, {Inna M} and Meyer, {N Helge} and Stephanie Schlichtner and Rohanah Hussain and Giuliano Siligardi and Maxwell Casely-Hayford and Walter Fiedler and Jasmin Wellbrock and Cloe Desmet and Luigi Calzolai and Luca Varani and Berger, {Steffen M} and Ulrike Raap and Gibbs, {Bernhard F} and Elizaveta Fasler-Kan and Sumbayev, {Vadim V}",
note = "Copyright {\textcopyright} 2020 Yasinska, Meyer, Schlichtner, Hussain, Siligardi, Casely-Hayford, Fiedler, Wellbrock, Desmet, Calzolai, Varani, Berger, Raap, Gibbs, Fasler-Kan and Sumbayev.",
year = "2020",
month = nov,
day = "20",
doi = "10.3389/fimmu.2020.580557",
language = "English",
volume = "11",
pages = "580557",
journal = "FRONT IMMUNOL",
issn = "1664-3224",
publisher = "Lausanne : Frontiers Research Foundation",

}

RIS

TY - JOUR

T1 - Ligand-Receptor Interactions of Galectin-9 and VISTA Suppress Human T Lymphocyte Cytotoxic Activity

AU - Yasinska, Inna M

AU - Meyer, N Helge

AU - Schlichtner, Stephanie

AU - Hussain, Rohanah

AU - Siligardi, Giuliano

AU - Casely-Hayford, Maxwell

AU - Fiedler, Walter

AU - Wellbrock, Jasmin

AU - Desmet, Cloe

AU - Calzolai, Luigi

AU - Varani, Luca

AU - Berger, Steffen M

AU - Raap, Ulrike

AU - Gibbs, Bernhard F

AU - Fasler-Kan, Elizaveta

AU - Sumbayev, Vadim V

N1 - Copyright © 2020 Yasinska, Meyer, Schlichtner, Hussain, Siligardi, Casely-Hayford, Fiedler, Wellbrock, Desmet, Calzolai, Varani, Berger, Raap, Gibbs, Fasler-Kan and Sumbayev.

PY - 2020/11/20

Y1 - 2020/11/20

N2 - Acute myeloid leukemia (AML), a blood/bone marrow cancer, is a severe and often fatal malignancy. AML cells are capable of impairing the anti-cancer activities of cytotoxic lymphoid cells. This includes the inactivation of natural killer (NK) cells and killing of T lymphocytes. Here we report for the first time that V-domain Ig-containing suppressor of T cell activation (VISTA), a protein expressed by T cells, recognizes galectin-9 secreted by AML cells as a ligand. Importantly, we found that soluble VISTA released by AML cells enhances the effect of galectin-9, most likely by forming multiprotein complexes on the surface of T cells and possibly creating a molecular barrier. These events cause changes in the plasma membrane potential of T cells leading to activation of granzyme B inside cytotoxic T cells, resulting in apoptosis.

AB - Acute myeloid leukemia (AML), a blood/bone marrow cancer, is a severe and often fatal malignancy. AML cells are capable of impairing the anti-cancer activities of cytotoxic lymphoid cells. This includes the inactivation of natural killer (NK) cells and killing of T lymphocytes. Here we report for the first time that V-domain Ig-containing suppressor of T cell activation (VISTA), a protein expressed by T cells, recognizes galectin-9 secreted by AML cells as a ligand. Importantly, we found that soluble VISTA released by AML cells enhances the effect of galectin-9, most likely by forming multiprotein complexes on the surface of T cells and possibly creating a molecular barrier. These events cause changes in the plasma membrane potential of T cells leading to activation of granzyme B inside cytotoxic T cells, resulting in apoptosis.

U2 - 10.3389/fimmu.2020.580557

DO - 10.3389/fimmu.2020.580557

M3 - SCORING: Journal article

C2 - 33329552

VL - 11

SP - 580557

JO - FRONT IMMUNOL

JF - FRONT IMMUNOL

SN - 1664-3224

ER -